Lv01
0 积分 2025-07-10 加入
An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs)
7小时前
已完结
Implementation of the principles of the 3Rs of animal testing at CDER: Past, present and future
7小时前
已完结
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies
7小时前
已完结
A Food and Drug Administration/Center for Drug Evaluation and Research nonclinical perspective on the use of human-induced pluripotent stem cell-derived cardiomyocyte data for cardiovascular safety assessment and regulatory decisions
7小时前
已完结
Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies
2个月前
已完结
Advancing alternative methods to reduce animal testing
2个月前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
5个月前
已完结
Structural insight into apelin receptor-G protein stoichiometry
5个月前
已完结
Transforming obesity: The advancement of multi-receptor drugs
5个月前
已完结
The unexpected role of GIP in transforming obesity treatment
5个月前
已完结
皖公网安备34019202002308
